



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|--|----------------------|------------------------|--------------|
| TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small> | Application Number | 10/530,499 | |
| | Filing Date | April 6, 2005 | |
| | First Named Inventor | Page | |
| | Art Unit | Unknown | |
| | Examiner Name | Unknown | |
| Total Number of Pages in This Submission | 5 | Attorney Docket Number | 100831-1P US |

| ENCLOSURES (Check all that apply) | | |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): |
| Remarks _____ | | |

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | | | |
|--|---|----------|--------|
| Firm Name | AstraZeneca | | |
| Signature |  | | |
| Printed name | Jianzhong Shen | | |
| Date | May 20, 2005 | Reg. No. | 48,076 |

| CERTIFICATE OF TRANSMISSION/MAILING | |
|---|---|
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: | |
| Signature |  |
| Typed or printed name | Liz Ashton |
| Date | May 20, 2005 |


This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No : 10/530,499 PCT Application No.: PCT/SE03/01604
Applicant : Pagé et al. PCT Filing Date: October 15, 2003
National Phase Fld (371): April 6, 2005
TC/A.U. : Unknown
Examiner : Unknown
Docket No. : 100831-1P US
Customer No. : 22466
Title : Novel Compounds

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on: May 20, 2005



Signature


Typed or printed name of person signing certificate

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant(s), wish to call the Examiner's attention to and make of record the references cited on the attached forms PTO/SB/08A and SB/08B. Applicants also wish to make the Examiner aware of co-pending applications: 10/474,549, a PCT national phase filed on April 18, 2002. Copies of the cited references, excluding the U.S. patent, are enclosed.


The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO/SB/08A and SB/08B forms.

Appl. No. 10/530,499

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

This Information Disclosure Statement is being filed within three months of the filing date of this application, and before the mailing date of a first office action on the merits and therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is required pursuant to 37 C.F.R. § 1.17(p).

Respectfully submitted,


Jianzhong Shen
Reg. No. 48,076
302-886-8854

Dated: May 20, 2005

Enclosures: Form PTO/SB/08A
Form PCT/SB/08B
References (14)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | |
|--|--------------------------|---------------|
| Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | Complete if Known | |
| | Application Number | 10/530,499 |
| | Filing Date | April 6, 2005 |
| | First Named Inventor | Pagé |
| | Art Unit | Unknown |
| | Examiner Name | Unknown |
| | Attorney Docket No. | 100831-1P US |
| SHEET 2 of 2 | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|-------------------------------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | STN International, file CAPLUS, CAPLUS accession no. 1973:87, document no. 78:87, Paglietti G. et al, "Dialkylaminoalkylbenzimidazoles of pharmacological interest", & Studi Sassaresi, Sezione 2: Archivio Bimestrale di Scienze Mediche e Naturali (1971), 49(5-6), 192-203 | <input type="checkbox"/> |
| | | SEKI, T. et al., "2-Benzimidazolethiol derivatives... -5-substituted, benzimidazole", Chem. Abstracts, 1969, pg. 445, Vol. 71, No. 13, THE ABSTRACT, No. 61291h, Yakugaku Zasshi, 1969, 89 (5), 617-626 | <input type="checkbox"/> |
| | | PAGLIETTI, G. et al., "Dialkylaminoalkylbenzimidazoles of pharmacological interest III", Chem. Abstracts, 1972, pg. 479, Vol. 77, No. 7, THE ABSTRACT, No. 48338h, Farmaco, Ed. Sci. 1972, 27 (4), 333-342 | <input type="checkbox"/> |
| | | LECOLIER, S. et al., "New benzimidazoles with morphine activity", Chim. Ther., 1967, pgs 16-24, Vol. 2, No. 1 | <input checked="" type="checkbox"/> |
| | | BURKE, T. et al., "Probes for Narcotic Receptor Mediated Phenomena. 7. ¹ Synthesis and Pharmacological Properties of Irreversible Ligands Specific for μ or δ Opiate Receptors", J. Med. Chem., 1984, pgs. 1570-1574, Vol. 27 | <input type="checkbox"/> |
| | | SMITH, J. et al., "Necklace-Coded Polymer-Supported Combinatorial Synthesis of 2-Arylamino benzimidazoles", J. Comb. Chem., 1999, pgs. 368-370, Vol. 1 | <input type="checkbox"/> |
| | | | <input type="checkbox"/> |
| | | | <input type="checkbox"/> |
| | | | <input type="checkbox"/> |
| | | | <input type="checkbox"/> |
| | | | <input type="checkbox"/> |
| | | | <input type="checkbox"/> |
| | | | <input type="checkbox"/> |
| | | | <input type="checkbox"/> |
| | | | <input type="checkbox"/> |
| Examiner Signature | /Niloofer Rahmani/ | | Date Considered 04/08/2008 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|----------------------|---------------|
| Application Number | 10/530,499 |
| Filing Date | April 6, 2005 |
| First Named Inventor | Pagé |
| Art Unit | Unknown |
| Examiner Name | Unknown |
| Attorney Docket No. | 100831-1P US |

SHEET 1 of 2

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number Number - Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|---|--------------------------------|--|---|
| | | US-2,945,044 | 7-12-1960 | Hoffmann et al. | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|--|--------------------------------|--|---|-------------------------------------|
| | | WO 97/19063 | 05-29-1997 | Sanofi | | <input type="checkbox"/> |
| | | WO 00/46209 | 08-10-2000 | Sanofi-Synthelabo | | <input type="checkbox"/> |
| | | WO 02/36590 | 05-10-2002 | Amrad Operations Pty Ltd | | <input type="checkbox"/> |
| | | WO 02/060447 | 08-08-2002 | University of Connecticut | | <input type="checkbox"/> |
| | | WO 02/085866 | 10-31-2002 | AstraZeneca AB | | <input type="checkbox"/> |
| | | WO 2004/035548 | 04-29-2004 | AstraZeneca AB | | <input type="checkbox"/> |
| | | EP 0445781 | 09-11-1991 | Sterling Drug Inc. | | <input type="checkbox"/> |
| | | FR 1481049 | 05-19-1967 | Serge Lécolier | | <input checked="" type="checkbox"/> |
| Examiner Signature | /Nilloofar Rahmani/ | | | Date Considered | 04/08/2008 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/